1. Introduction {#sec1-molecules-21-00271}
===============

The development of new antitumor agents is an important field of scientific activity, due to the toxic side effect problems of recent drugs. Many of the obtainable anticancer agents display unwanted side effects such as reduced bioavailability, toxicity and drug-resistance \[[@B1-molecules-21-00271],[@B2-molecules-21-00271],[@B3-molecules-21-00271],[@B4-molecules-21-00271],[@B5-molecules-21-00271]\]. Incorporation of a pyrazole ring into different heteroaryl ring systems results in significant anticancer activities \[[@B6-molecules-21-00271],[@B7-molecules-21-00271],[@B8-molecules-21-00271],[@B9-molecules-21-00271]\]. Different substituted pyrazole compounds have also been examined for their antiproliferative activities *in vitro* and antitumor activity *in vivo*, resulting in promising target products \[[@B10-molecules-21-00271],[@B11-molecules-21-00271],[@B12-molecules-21-00271]\]. On the other hand, compounds containing pyrazole derivatives represent an advantageous choice for the synthesis of compounds with a broad spectrum of pharmacological activities, including anti-inflammatory \[[@B13-molecules-21-00271]\], antibacterial, antifungal \[[@B14-molecules-21-00271]\], inhibition of cyclooxygenase-2 \[[@B15-molecules-21-00271]\], antiangiogenic \[[@B16-molecules-21-00271]\], antipyretic \[[@B17-molecules-21-00271]\], antihypertensive \[[@B18-molecules-21-00271]\], antiplatelet \[[@B19-molecules-21-00271]\], nitric oxide synthase (NOS) inhibitors \[[@B20-molecules-21-00271]\] and anticancer activities \[[@B21-molecules-21-00271]\]. Based on these observations and in continuation of our research on biologically active heterocycles \[[@B22-molecules-21-00271],[@B23-molecules-21-00271],[@B24-molecules-21-00271],[@B25-molecules-21-00271]\], it was of interest to incorporate the 1,2,4-polysubstituted pyrazole ring system into different heteroaryl ring systems in one molecule in an attempt to obtain a new target anticancer agents.

2. Results and Discussion {#sec2-molecules-21-00271}
=========================

2.1. Chemistry {#sec2dot1-molecules-21-00271}
--------------

The reaction sequences outlined in [Scheme 1](#molecules-21-00271-f001){ref-type="scheme"} and [Scheme 2](#molecules-21-00271-f002){ref-type="scheme"} were used for the synthesis of the target compounds. Application of the Claisen Schmidt condensation on 2-acetylthiophene and 1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1*H*-pyrazole-4-carboxaldehyde (**1**) in ethanolic sodium hydroxide solution according to literature methods \[[@B26-molecules-21-00271],[@B27-molecules-21-00271]\] afforded (*E*)-3-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1*H*-pyrazol-4-yl)-1-(thiophen-2-yl)prop-2-en-1-one (**2**), which was used as starting material. Cyclocondensation of the α,β-unsaturated ketone **2** with hydrazine hydrate in absolute ethanol or glacial acetic acid yielded the corresponding pyrazoline derivative **3** and N-acetyl-pyrazoline derivative **4**, respectively. On the other hand, heating of **2** with thiosemicarbazide in ethanolic NaOH gave 1-thiocarbamoyl pyrazole derivative **5**. In addition, condensation of compound **1** with ethyl cyanoacetate, or ethyl acetoacetate in the presence of guanidine hydrochloride gave 2-amino-5-cyano/acetyl-6-hydroxy-4-aryl pyrimidines **6a**,**b**, respectively ([Scheme 1](#molecules-21-00271-f001){ref-type="scheme"}).

Finally, α,β-unsaturated ketone **2** was reacted with hydroxylamine hydrochloride in refluxing ethanol in the presence of sodium hydroxide as alkaline medium to afford the corresponding isoxazoline **7**. Treatment of **2** with guanidine sulfate in ethanolic sodium hydroxide gave 2-aminopyrimidine derivative **8**, which was reacted with thiourea in the presence of sodium hydroxide to give the corresponding pyrimidine-2-thione derivative **9** ([Scheme 2](#molecules-21-00271-f002){ref-type="scheme"}).

2.2. In Vitro Anticancer Screening {#sec2dot2-molecules-21-00271}
----------------------------------

The target compounds were selected by the U.S. National Cancer Institute (NCI), for anticancer activity screening. The screening is a two-stage process, beginning with the evaluation at a single dose (10 µM) and the compounds which display significant growth inhibition are then evaluated at five concentration levels. The first screening, where the selected compounds are evaluated at a single dose (10 µM) and the culture is incubated for 48 h, utilizes 60 different human tumor cell lines, representing leukemia, melanoma and cancers of lung, colon, central nervous system (CNS), ovary, kidney, prostate as well as breast.

The percentages of growth of the tested compounds against the full 60-cell line panel are listed in [Table 1](#molecules-21-00271-t001){ref-type="table"}. The one dose mean graphs of the selected compounds revealed that compounds **6a**, **7** and **9** showed increased potency against most human cancer cell lines, so these compounds were selected for further evaluation at five dose concentration levels (0.01--100 µM).Regarding sensitivity against individual cell lines, compound **9** showed potent anticancer activity against all human cancer cell lines with GI~50~ 1.9--5.50 µM. It had the highest selectivity against the non-small cell lung cancer cell line EKVX, with GI~50~ 1.9 µM. At the same time, compounds **6a** and **7** showed the highest activity against the cell line HOP-92 belonging to the non-small cell lung cancer class with GI~50~ 1.7 and 1.6 µM, respectively, and against the renal cancer cell line A498 with GI~50~ 1.47 and 1.81 µM, respectively.

Examination of all the ligand structural modifications performed at the 4-position of 1,3,4-trisubstituted pyrazole scaffold to establish the structure activity relationships with anticancer acitivity shows the following results: first, introduction of the pyrimidine-2(1*H*)-thione moiety in the 4-position of the pyrazole moiety in compound **9** enhanced the potency towards most cancer cell lines. It has GI~50~ MG-MID = 3.6 µM against all subpanel tumor cell lines, comparable to that of sorafenib (GI~50~ MG-MID = 1.90 µM. Concerning the pyrazolyl derivative **6a**, it was observed that the activity was enhanced in 2-amino-6-oxopyrimidine-5-carbonitrile, which suggests that the polar 6-aminopyrimidine moiety has a role in enhancing anticancer activity (GI~50~ MG-MID = 5.70 µM), but less so than the 2-mercaptopyrimidine group. Finally, introduction of a 1-carbothioamide to a pyrazole or isoxazoline group substituted on the pyrazole greatly reduces the activity and these compounds showed the least potent activity. The results are presented in [Table 1](#molecules-21-00271-t001){ref-type="table"}, [Table 2](#molecules-21-00271-t002){ref-type="table"}, [Table 3](#molecules-21-00271-t003){ref-type="table"}, [Table 4](#molecules-21-00271-t004){ref-type="table"}, [Table 5](#molecules-21-00271-t005){ref-type="table"} and [Table 6](#molecules-21-00271-t006){ref-type="table"}.

3. Experimental Section {#sec3-molecules-21-00271}
=======================

3.1. General Information {#sec3dot1-molecules-21-00271}
------------------------

Melting points were measured in open capillary tubes using a Griffin apparatus and are uncorrected. Structures of compounds were confirmed by routine spectrometric analysis. Elemental analyses were carried results were within ±0.4% of the theoretical values. Infrared spectra were recorded on a 435 IR spectrophotometer (Shimadzu Bruker, Tokyo, Japan) using KBr discs. ^1^H-NMR and ^13^C-NMR spectra were obtained on a Gemini 500 MHz spectrophotometer (Varian, Polo Alto, Ca, USA) or on a Bruker 500 MHz spectrophotometer, and measured in δ scale using TMS as an internal standard. Mass Spectra were recorded on a 5988 spectrometer (Hewlett Packard, California, USA). Analytical thin layer chromatography (TLC) was performed using silica gel aluminum sheets, 60 F~254~ (E. Merck, Darmstadt, Germany) for the progress of reactions and visualization with ultraviolet light (UV) at 365 and 254 nm.

3.2. 3-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-1-(thiophen-2-yl)prop-2-en-1-one (***2***) {#sec3dot2-molecules-21-00271}
----------------------------------------------------------------------------------------------------------

A mixture of carbaldehyde derivative **1** (0.01 mol) and 2-acetylthiophene (0.01 mol) in of 30% ethanolic solution of NaOH (40 mL) was stirred for 12 h at room temperature. The progress of reaction was monitored by TLC. After completion, the reaction mixture was poured into acidified ice cold water of pH\~2. The precipitated solid was filtered, washed with water and recrystallized to afford compound **2** in 87% yield; m.p. 144--146 °C (EtOH); IR (KBr) ν: 3079 (CH-Ar), 1641 (C=O), 1600 (C=C) cm^−1^; ^1^H-NMR (DMSO-*d*~6~): δ 3.81 (s, ^3^H, OCH~3~); 7.00--7.98 (m, ^12^H, ArH + CH=CH), 8.73 (s,^1^H, CH of pyrazole) ppm; ^13^C-NMR (DMSO-*d*~6~): δ 55.60, 114.34, 116.62, 117.75, 125.11, 125.95, 127.67, 129.08, 129.81, 131.74, 133.85, 134.47, 135.44, 141.08, 144.32, 151.54, 159.58, 191.96 ppm; MS (EI, 70 eV): *m*/*z* (%): 420 (11) \[M\]^+^; Anal. Calcd for C~23~H~17~ClN~2~O~2~S (420.91): C, 65.63; H, 4.07; N, 6.66; Found: C, 65.59; H, 4.16; N, 6.72.

3.3. 1-(3-Chlorophenyl)-4-(4,5-dihydro-3-(thiophen-2-yl)-1H-pyrazol-5-yl)-3-(4-methoxyphenyl)-1H-pyrazole *(**3**)* {#sec3dot3-molecules-21-00271}
-------------------------------------------------------------------------------------------------------------------

To a solution of compound **2** (0.01 mol) in ethanol (30 mL) containing a catalytic amount of glacial acetic acid, a solution of hydrazine hydrate (98%, 0.5 mL) was added and the mixture was refluxed for 6 h. The reaction mixture was cooled to room temperature and the precipitated solid was filtered, dried and recrystallization provided compound **3** in 57% yield; m.p. 175--178 °C (EtOH); IR (KBr) ν: 3177 (NH), 1590 (C=C) cm^−1^; ^1^H-NMR (DMSO-*d*~6~): δ 2.99 (dd, ^1^H, CH), 3.70 (s, ^3^H, OCH~3~), 3.84 (dd, ^1^H, CH), 5.42 (dd, ^1^H, CH), 6.39--7.77 (m, ^11^H, Ar-H), 8.91 (s, ^1^H, CH of pyrazole), 11.52 (s, ^1^H, NH D~2~O exchangeable) ppm; ^13^C-NMR (DMSO-*d*~6~): δ 42.10, 55.61, 60.74, 114.22, 116.78, 117.76, 125.18, 125.90, 126.17, 127.38, 128.67, 129.65, 130.87, 131.26, 134.53, 137.55, 140.98, 151.24, 159.73, 158.76, 161.48 ppm; MS (EI, 70 eV): *m*/*z* (%): 434 (18) \[M\]^+^; Anal. Calcd for C~23~H~19~ClN~4~OS (434.94): C, 63.51; H, 4.40; N, 12.88; Found: C, 63.59; H, 4.53; N, 12.92.

3.4. 1-(5-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-4,5-dihydro-3-(thiophen-2yl)pyrazol-1-yl)-ethanone *(**4**)* {#sec3dot4-molecules-21-00271}
-------------------------------------------------------------------------------------------------------------------------------

To a solution of compound **2** (0.01 mol) in glacial acetic acid (20 mL), hydrazine hydrate (0.01 mol) was added and the mixture was refluxed for 3 h. The reaction mixture was cooled to room temperature and the solid formed was filtered off, dried and recrystallized to get compound 4 in 65% yield; m.p. 150--154 °C (EtOH); IR (KBr) ν: 3080 (CH-Ar), 1677 (C=O), 1619 (C=N), 1588 (C=C) cm^−1^; ^1^H-NMR (DMSO-*d*~6~): 2.43 (s, ^3^H, COCH~3~), 3.30 (dd, ^1^H, CH), 3.81 (s, ^3^H, OCH~3~), 3.88 (dd, ^1^H, CH), 5.57 (dd, ^1^H, CH), 6.70--7.65 (m, ^11^H, Ar-H), 9.18 (s, ^1^H, CH of pyrazole) ppm; ^13^C-NMR (DMSO-*d*~6~): δ 24.01, 43.81, 55.60, 63.87, 114.26, 116.84, 117.62, 125.35, 125.86, 126.10, 127.56, 129.14, 129.78, 130.69, 131.08, 134.41, 137.82, 140.84, 150.39, 155.19, 159.12, 160.92, 168.19 ppm; MS (EI, 70 eV): *m*/*z* (%): 476 (43) \[M\]^+^; Anal. Calcd for C~25~H~21~ClN~4~O~2~S (476.98): C, 62.95; H, 4.44; N, 11.75; Found: C, 63.02; H, 4.35; N, 11.81.

3.5. 5-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-4,5-dihydro-3-(thiophen-2-yl)-pyrazole-1-carbothioamide *(**5**)* {#sec3dot5-molecules-21-00271}
---------------------------------------------------------------------------------------------------------------------------------

To a mixture of chalcone **2** (0.01 mol) in absolute ethanol (30 mL), sodium hydroxide (1 g, 0.025 mol) was added. The reaction mixture was heated under reflux for 5 h. The contents were reduced, cooled and poured onto crushed ice. The resulting precipitate was collected by filtration and recrystallized to give in 61% yield; m.p. \>300 °C (MeOH); IR (KBr) ν: 3407 (NH~2~), 1658 (C=N), 1523 (C=C), 1078 (C=S) cm^−1^; ^1^H-NMR (DMSO-*d*~6~): 3.13 (dd, ^1^H, CH), 3.84 (s, ^3^H, OCH~3~), 4.14 (dd, ^1^H, CH), 5.51 (dd, ^1^H, CH), 7.14--8.02 (m, ^11^H, Ar-H), 9.12 (s, ^1^H, CH of pyrazole), 9.93 (s, ^2^H, NH~2~ D~2~O exchangeable) ppm; ^13^C-NMR (DMSO-*d*~6~): δ 43.14, 55.64, 62.93, 114.33, 116.72, 117.58, 125.37, 125.80, 126.08, 127.54, 128.79, 129.22, 130.65, 131.16, 138.12, 137.82, 140.85, 151.23, 156.19, 159.30, 161.02, 176.55 ppm; MS (EI, 70 eV): *m*/*z* (%): 494 (6) \[M\]^+^; Anal. Calcd for C~24~H~20~ClN~5~OS~2~ (494.03): C, 58.35; H, 4.08; N, 14.18; Found: C, 58.27; H, 4.12; N, 14.23.

3.6. 2-Amino-4-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-1,6-dihydro-6-oxopyrimidine-5-carbonitrile *(**6a**)* and 5-acetyl-2-amino-6-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-pyrimidin-4(3H)-one *(**6b**)* {#sec3dot6-molecules-21-00271}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A mixture of compound **1** (0.01 mol), ethyl cyanoacetate or ethyl acetoacetate (0.01 mol) and (5 mL) of 40% ethanolic sodium hydroxide was stirred for 10 min, followed by addition of guanidine hydrochloride (0.01 mol) and the heating continued under refluxed for 3 h. The reaction mixture was diluted with ice-water and the formed precipitate was collected by filtration, washed several times with water, dried and recrystallized to afford the title compounds **6a**,**b**.

*2-Amino-4-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-1,6-dihydro-6-oxopyrimidine-5-carbonitrile* (**6a**). Yield 64%; m.p. 144--148 °C (EtOH); IR (KBr) ν: 3341, 3145 (NH~2~, NH), 2219 (C≡N), 1663 (C=O), 1599 (C=C) cm^−1^; ^1^H-NMR (DMSO-*d*~6~): 2.85 (s, ^2^H, NH~2~ D~2~O exchangeable), 3.88 (s, ^3^H, OCH~3~), 7.03--8.75 (m, ^9^H, Ar-H and NH D~2~O exchangeable), 9.20 (s, ^1^H, CH of pyrazole) ppm; ^13^C-NMR (DMSO-*d*~6~): δ 55.63, 113.75, 115.31, 116.79, 117.77, 123.48, 125.21, 126.4, 127.94, 128.30, 129.82, 130.80, 134.57, 140.89, 155.04, 159.88, 160.60, 164.33, 171.88 ppm; MS (EI, 70 eV): *m*/*z* (%): 418 (14) \[M\]^+^; Anal. Calcd for C~21~H~15~ClN~6~O~2~ (418.84): C, 60.22; H, 3.61; N, 20.07; Found: C, 60.26; H, 3.58; N, 20.15.

*5-Acetyl-2-amino-6-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)pyrimidin-4-(3H)-one* (**6b**). Yield 68%, m.p. 135--137 °C (EtOH); IR (KBr) ν: 3410, 3152 (NH~2~,NH), 1675 (C=O), 1589 (C=C) cm^−1^; ^1^H-NMR (DMSO-*d*~6~): 2.30 (s, ^2^H, NH~2~ D~2~O exchangeable), 2.39 (s, ^3^H, CH~3~), 3.86 (s, ^3^H, OCH~3~), 6.90--7.96 (m, ^9^H, Ar-H and NH exchangeable with D~2~O), 9.14 (s, ^1^H, CH of pyrazole) ppm; ^13^C-NMR (DMSO-*d*~6~): δ 24.38, 55.60, 113.72, 115.94, 116.85, 117.73, 125.10, 126.01, 128.36, 130.76, 132.95, 134.47, 141.05, 151.14, 154.78, 159.60, 160.82, 164.21, 165.38, 182.70 ppm; MS (EI, 70 eV): *m*/*z* (%): 435 (7) \[M\]^+^; Anal. Calcd for C~22~H~18~ClN~5~O~3~ (435.86): C, 60.62; H, 4.16; N, 16.07; Found: C, 60.59; H, 4.11; N, 16.12.

3.7. 1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-4-(3-(thiophen-2-yl)isoxazol-5-yl)-1H-pyrazole *(**7**)* {#sec3dot7-molecules-21-00271}
----------------------------------------------------------------------------------------------------

A mixture of compounds **2** (0.01 mol) and hydroxylamine hydrochloride (0.01 mol) in ethanol (30 mL) containing sodium hydroxide solution (0.5 g NaOH in 0.5 mL water) was refluxed for 3 h. The reaction mixture was poured onto ice-water, neutralized with drops of conc. Hydrochloric acid and the solid precipitate formed filtered off, washed with water and recrystallized to yield the desired compound **7** in 73% yield; m.p. \>300 °C (EtOH); IR (KBr) ν: 3064 (CH-Ar), 1601 (C=C) cm^−1^; ^1^H-NMR (DMSO-*d*~6~): 3.99 (s, ^3^H, OCH~3~), 7.30 (d, ^2^H, H *J* = 20), 7.60 (d, ^1^H, CH); 7.75--8.45 (m, ^10^H, Ar-H), 9.15 (s, ^1^H, CH of pyrazole) ppm; ^13^C-NMR (DMSO-*d*~6~): δ 43.19, 55.61, 73.10, 114.38, 116.72, 117.68, 125.68, 125.84, 126.10, 127.43, 129.07, 129.57, 130.81, 131.29, 134.47, 138.21, 140.85, 151.20, 154.63, 160.92, 162.89 ppm; MS (EI, 70 eV): *m*/*z* (%): 433 (12) \[M\]^+^; Anal. Calcd for C~23~H~16~ClN~3~O~2~S (433.91): C, 63.66; H, 3.72; N, 9.68; Found: C, 63.74; H, 3.79; N, 9.71.

3.8. 4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-6-(thiophen-2-yl)pyrimidin-2-amine *(**8**)* {#sec3dot8-molecules-21-00271}
------------------------------------------------------------------------------------------------------------

An aqueous solution 5 mL of 40% sodium hydroxide was added gradually during a period of 3 h to a mixture of chalcone **2** (0.01 mol) and guanidine sulfate (0.01 mol) in ethanol (25 mL). The reaction mixture was refluxed for 5 h and the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was poured onto ice-cold water and the solid product formed was collected by filtration, washed with water then recrystallized to get compound **8** in 67% yield; m.p. \>300 °C (MeOH); IR (KBr) *ν*: 3347 (NH~2~); 1632 (C=N); 1589 (C=C) cm^−1^; ^1^H-NMR (DMSO-*d*~6~): 3.80 (s, ^3^H, OCH~3~), 6.68-8.08 (t, ^12^H, Ar-H), 8.93 (s,^1^H, CH of pyrazole), 10.18 (s, ^2^H, NH~2~ D~2~O exchangeable) ppm; ^13^C-NMR (DMSO-*d*~6~): δ 55.64, 82.10, 114.31, 116.80, 117.59, 125.30, 125.78, 126.09, 127.41, 128.67, 129.48, 130.79, 131.16, 134.49, 139.86, 141.05, 150.88, 152.10, 160.37, 164.21, 166.58, 164.25 ppm; Anal. Calcd for C~24~H~18~ClN~5~OS (459.95): C, 62.67; H, 3.94; N, 15.23; Found: C, 62.63; H, 3.88; N, 15.29.

3.9. 6-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-4-(thiophen-2-yl)pyrimidine-2-(1H)-thione *(**9**)* {#sec3dot9-molecules-21-00271}
-------------------------------------------------------------------------------------------------------------------

A solution of the chalcone **2** (0.01 mol), thiourea (0.01 mol) and sodium hydroxide (0.1 g) in absolute ethanol (30 mL) was refluxed for 6 h. The reaction mixture was concentrated under vacuum, cooled and neutralized with dilute HCl. The formed product was filtered off, washed with water and recrystallized to get compound **9** in 76% yield; m.p. \>300 °C (MeOH); IR (KBr) ν: 3422 (NH), 1595 (C=C), 1176 (C=S) cm^−1^; ^1^H-NMR (DMSO-*d*~6~): 3.82 (s, ^3^H, OCH~3~), 6.90--8.60 (m, ^12^H, Ar-H), 9.20 (s, ^1^H, CH of pyrazole), 9.95 (s, ^1^H, NH D~2~O exchangeable) ppm; ^13^C-NMR (DMSO-*d*~6~): δ 55.63, 104.56, 113.82, 115.89, 117.66, 125.38, 125.70, 126.03, 127.38, 128.34, 129.45, 130.77, 131.09, 134.42, 138.17, 140.95, 150.76, 157.21, 160.85, 161.80, 162.46, 184.33 ppm; MS (EI, 70 eV): 477 (8) \[M\]^+^; Anal. Calcd for C~24~H~17~ClN~4~OS~2~ (477): C, 60.43; H, 3.59; N, 11.75; Found: C, 60.38; H, 3.66; N, 11.82.

3.10. Measurement of Anticancer Activity {#sec3dot10-molecules-21-00271}
----------------------------------------

The experimental method used in anticancer screening has been adopted by U.S. National Cancer Institute according to reported standard procedure \[[@B28-molecules-21-00271],[@B29-molecules-21-00271],[@B30-molecules-21-00271]\].

4. Conclusions {#sec4-molecules-21-00271}
==============

In summary, we have synthesized a series of novel pyrazole derivatives incorporated different heteroaryl ring systems in one molecule and evaluated these compounds for their anticancer activities against different 60 human cancer cell lines representing leukemia, melanoma and cancers of lung, colon, brain, ovary, breast, prostate and kidney cancer using a two-stage process. The pyrimidine-2(1*H*)-thione derivative **9** showed good anticancer activity with (GI~50~ MG-MID = 3.59 µM) compared to the standard drug sorafenib. The structures of the new compounds were elucidated using spectroscopic and elemental analysis.
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Schemes and Tables
==================

![Synthetic route for trisubstituted pyrazole compounds **2**--**6**.](molecules-21-00271-g001){#molecules-21-00271-f001}

![Synthetic route for trisubstituted pyrazole compounds **7**--**9**.](molecules-21-00271-g002){#molecules-21-00271-f002}

molecules-21-00271-t001_Table 1

###### 

The mean growth percent of compounds **2**, **3**, **4**, **6a**, **6b**, **7**, **8** and **9**.

  Cpd. No.   NSC No.    Mean Growth Percent
  ---------- ---------- ---------------------
  **2**      762925/1   95.56
  **3**      763580/1   102.40
  **4**      763581/1   98.43
  **6a**     762930/1   67.27
  **6b**     762931/1   76.45
  **7**      762927/1   47.83
  **8**      762928/1   99.26
  **9**      762929/1   49.53

molecules-21-00271-t002_Table 2

###### 

GI~50~ (μM) of five-dose screening results of compounds **6a**, **7** and **9**.

  Subpanel Cell Lines                              
  -------------------------------- ------- ------- ------
  **Leukemia**                                     
  **CCRF-CEM**                     3.65    3.84    2.80
  **HL-60(TB)**                    3.96    4.73    3.49
  **K-562**                        3.45    3.43    2.91
  **MOLT-4**                       4.80    2.96    3.03
  **RPMI-8226**                    5.63    5.33    2.42
  **SR**                           3.73    3.03    4.00
  **Non-Small Cell Lung Cancer**                   
  **A549/ATCC**                    5.13    3.56    2.29
  **EKVX**                         3.29    2.07    1.93
  **HOP-62**                       10.1    13.90   7.14
  **HOP-92**                       1.65    1.61    2.20
  **NCI-H226**                     6.23    4.11    3.16
  **NCI-H23**                      5.44    3.82    3.43
  **NCI-H460**                     6.00    3.42    3.01
  **NCI-H522**                     3.11    4.27    2.54
  **NCI-H322M**                                    
  **Colon Cancer**                                 
  **COLO 205**                     7.65    3.21    2.35
  **HCC-2998**                     5.87    3.47    4.03
  **HCT-116**                      4.35    3.03    2.38
  **HCT-15**                       5.07    4.48    3.69
  **HT29**                         4.29    3.85    3.82
  **KM12**                         3.84    2.98    3.67
  **SW-620**                       4.38    4.35    3.79
  **CNS Cancer**                                   
  **SF-268**                       5.86    4.94    4.52
  **SF-295**                       2.36    2.70    2.07
  **SF-539**                       6.59    7.47    4.70
  **SNB-19**                       4.58    6.08    4.93
  **SNB-75**                       2.88    3.52    3.49
  **U251**                         3.66    3.61    2.60
  **Melanoma**                                     
  **LOX IMVI**                     4.02    3.04    3.56
  **MALME-3M**                     5.83    2.60    3.49
  **M14**                          3.25    3.30    2.81
  **MDA-MB-435**                   2.16    3.26    3.13
  **SK-MEL-2**                     3.94    3.34    2.87
  **SK-MEL-28**                    4.98    4.93    3.93
  **SK-MEL-5**                     4.07    4.74    2.93
  **UACC-257**                     5.69    3.07    3.06
  **UACC-62**                      3.33    3.55    2.78
  **Ovarian Cancer**                               
  **IGROV1**                       3.01    4       3.61
  **OVCAR-3**                      3.38    5.07    3.04
  **OVCAR-4**                      7.71    4.48    3.47
  **OVCAR-5**                      14.60   7.63    6.38
  **OVCAR-8**                      10.10   4.04    3.15
  **NCI/ADR-RES**                  3.33    4.01    4.77
  **SK-OV-3**                      6.56    8.89    5.91
  **Renal Cancer**                                 
  **786-0**                        4.65    3.39    4.18
  **A498**                         1.47    1.81    3.01
  **ACHN**                         9.92    4.39    4.05
  **CAKI-1**                       2.52    2.05    3.03
  **RXF 393**                      4.51    3.49    3.76
  **SN12C**                        6.41    3.48    3.92
  **TK-10**                        13.50   5.21    4.55
  **UO-31**                        2.94    2.56    2.82
  **Prostate Cancer**                              
  **PC-3**                         6.30    3.2     3.09
  **DU-145**                       17.9    7.08    5.49
  **Breast Cancer**                                
  **MCF7**                         3.54    3.53    3.02
  **MDA-MB-231/ATCC**              3.39    3.08    3.52
  **HS 578T**                      3.55    4.42    4.26
  **BT-549**                       3.55    4.99    3.18
  **T-47D**                        6.05    3.86    4.16
  **MDA-MB-468**                   2.12    2.68    2.57

GI~50~: (growth inhibitory activity) the drug concentration that reduces cellular growth by 50%.

molecules-21-00271-t003_Table 3

###### 

TGI (μM) of five-dose screening results of compounds **6a**, **7** and **9**.

  Subpanel Cell Lines                               
  -------------------------------- -------- ------- -------
  **Leukemia**                                      
  **CCRF-CEM**                     33.80    \>100   \>100
  **HL-60(TB)**                    14.20    38.30   13.20
  **K-562**                        \>100    \>100   \>100
  **MOLT-4**                       39.80    19.50   25.20
  **RPMI-8226**                    55.50    61.90   10.90
  **SR**                           21.20    12.10   31.90
  **Non-Small Cell Lung Cancer**                    
  **A549/ATCC**                    50.80    24.50   16.50
  **EKVX**                         35.40    13.50   21.70
  **HOP-62**                       26.20    28.10   22.10
  **HOP-92**                       12.20    8.13    10.80
  **NCI-H226**                     70.300   30.30   54.40
  **NCI-H23**                      46.20    20.80   16.20
  **NCI-H460**                     27.70    16.60   11.00
  **NCI-H522**                     9.80     18.40   8.86
  **NCI-H322M**                                     
  **COLO 205**                     20.90    7.24    5.59
  **HCC-2998**                     24.90    14.60   16.40
  **HCT-116**                      16.20    12.70   11.20
  **HCT-15**                       \>100    32.90   \>100
  **HT29**                         20.00    15.10   13.00
  **KM12**                         15.20    11.10   14.40
  **SW-620**                       34.20    22.60   22.30
  **CNS Cancer**                                    
  **SF-268**                       35.4     47.10   73.60
  **SF-295**                       9.22     13.20   7.09
  **SF-539**                       32.2     36.60   19.70
  **SNB-19**                       100      \>100   \>100
  **SNB-75**                       21.1     34.70   25.60
  **U251**                         18.8     15.40   12.40
  **Melanoma**                                      
  **LOX IMVI**                     20.10    10.90   13.80
  **MALME-3M**                     40.60    10.60   15.80
  **M14**                          34.00    17.10   14.00
  **MDA-MB-435**                   5.48     17.30   19.00
  **SK-MEL-2**                     15.80    10.90   6.90
  **SK-MEL-28**                    27.90    17.80   15.70
  **SK-MEL-5**                     15.90    17.30   10.90
  **UACC-257**                     47.30    15.10   18.00
  **UACC-62**                      15.40    20.00   19.20
  **Ovarian Cancer**                                
  **IGROV1**                       18.10    16.20   15.30
  **OVCAR-3**                      10.00    25.00   9.42
  **OVCAR-4**                      61.90    36.40   \>100
  **OVCAR-5**                      51.40    74.10   \>100
  **OVCAR-8**                      60.30    36.00   \>100
  **NCI/ADR-RES**                  15.90    38.10   41.80
  **SK-OV-3**                      30.70    44.10   36.80
  **Renal Cancer**                                  
  **786-0**                        33.50    \>100   \>100
  **A498**                         6.75     14.60   17.00
  **ACHN**                         \>100    \>100   \>100
  **CAKI-1**                       15.30    6.02    8.68
  **RXF 393**                      22.40    20.10   19.50
  **SN12C**                        \>100    18.70   \>100
  **TK-10**                        53.90    43.80   32.80
  **UO-31**                        47.80    11.80   26.50
  **Prostate Cancer**                               
  **PC-3**                         \>100    36.90   \>100
  **DU-145**                       70.10    35.80   72.50
  **Breast Cancer**                                 
  **MCF7**                         28.50    16.90   33.40
  **MDA-MB-231/ATCC**              53.30    16.90   26.00
  **HS 578T**                      40.30    45.50   \>100
  **BT-549**                       22.40    21.30   15.90
  **T-47D**                        32.20    25.30   34.60
  **MDA-MB-468**                   6.43     12.30   9.91

TGI: the drug concentration required for total growth inhibition.

molecules-21-00271-t004_Table 4

###### 

LC~50~ (μM) of five-dose screening results of compounds **6a**, **7** and **9**.

  Subpanel Cell Lines                              
  -------------------------------- ------- ------- -------
  **Leukemia**                                     
  **CCRF-CEM**                     \>100   \>100   \>100
  **HL-60(TB)**                    \>100   \>100   \>100
  **K-562**                        \>100   \>100   \>100
  **MOLT-4**                       \>100   \>100   \>100
  **RPMI-8226**                    \>100   \>100   \>100
  **SR**                           \>100   \>100   \>100
  **Non-Small Cell Lung Cancer**                   
  **A549/ATCC**                    \>100   \>100   \>100
  **EKVX**                         \>100   \>100   \>100
  **HOP-62**                       67.80   56.90   59.80
  **HOP-92**                       \>100   \>100   83.20
  **NCI-H226**                     \>100   \>100   \>100
  **NCI-H23**                      \>100   \>100   \>100
  **NCI-H460**                     \>100   \>100   52.00
  **NCI-H522**                     \>100   93.50   \>100
  **NCI-H322M**                                    
  **Colon Cancer**                                 
  **COLO 205**                     \>50    24.70   40.00
  **HCC-2998**                     \>100   64.70   96.00
  **HCT-116**                      46.00   40.60   33.80
  **HCT-15**                       \>100   \>100   \>100
  **HT29**                         \>100   \>100   46.90
  **KM12**                         49.70   84.60   49.30
  **SW-620**                       \>100   \>100   \>100
  **CNS Cancer**                                   
  **SF-268**                       \>100   \>100   \>100
  **SF-295**                       84.70   \>100   61.30
  **SF-539**                       \>100   \>100   82.30
  **SNB-19**                       \>100   \>100   \>100
  **SNB-75**                       \>100   \>100   \>100
  **U251**                         82.80   49.50   38.30
  **Melanoma**                                     
  **LOX IMVI**                     74.10   54.90   45.20
  **MALME-3M**                     \>100   60.00   97.20
  **M14**                          \>100   84.10   90.10
  **MDA-MB-435**                   \>100   \>100   \>100
  **SK-MEL-2**                     99.10   66.80   35.60
  **SK-MEL-28**                    \>100   52.40   58.80
  **SK-MEL-5**                     51.30   47.50   41.90
  **UACC-257**                     \>100   \>100   \>100
  **UACC-62**                      53.30   65.70   71.60
  **Ovarian Cancer**                               
  **IGROV1**                       \>100   71.20   73.80
  **OVCAR-3**                      60.30   \>100   35.90
  **OVCAR-4**                      \>100   \>100   \>100
  **OVCAR-5**                      \>100   100     \>100
  **OVCAR-8**                      \>100   \>100   \>100
  **NCI/ADR-RES**                  \>100   \>100   \>100
  **SK-OV-3**                      \>100   \>100   \>100
  **Renal Cancer**                                 
  **786-0**                        \>100   \>100   \>100
  **A498**                         \>100   45.20   73.20
  **ACHN**                         \>100   \>100   \>100
  **CAKI-1**                       \>100   75.90   \>100
  **RXF 393**                      \>100   \>100   \>100
  **SN12C**                        \>100   \>100   \>100
  **TK-10**                        \>100   \>100   \>100
  **UO-31**                        \>100   \>100   \>100
  **Prostate Cancer**                              
  **PC-3**                         \>100   \>100   \>100
  **DU-145**                       \>100   \>100   \>100
  **Breast Cancer**                                
  **MCF7**                         \>100   83.60   \>100
  **MDA-MB-231/ATCC**              \>100   \>100   \>100
  **HS 578T**                      \>100   \>100   \>100
  **BT-549**                       \>100   66.30   \>100
  **T-47D**                        \>100   \>100   \>100
  **MDA-MB-468**                   \>100   \>100   \>100

LC~50~: the drug concentration required for killing 50% of cells.

molecules-21-00271-t005_Table 5

###### 

Median growth inhibitory concentrations (GI~50~, μM) of *in vitro* subpanel tumor cell lines and GI~50~ (μM) full panel mean-graph mid-points (MG-MID) of compounds **6a**, **7** and **9** in comparison with sorafenib.

  Subpanel Tumor Cell Lines                                                          
  --------------------------- ----- ----- ----- ----- ----- ----- ----- ------ ----- -----
  **6a**                      4.2   5.1   5.1   4.3   4.1   7.0   5.7   12.1   3.7   5.7
  **7**                       3.9   4.6   3.6   4.7   3.5   5.5   3.3   5.1    3.8   4.2
  **9**                       3.1   3.2   3.4   3.7   3.2   4.3   3.7   4.3    3.5   3.6
  **Sorafenib**                                                                      1.9

molecules-21-00271-t006_Table 6

###### 

Selectivity ratios for compounds **6a**, **7** and **9** towards the nine tumor cell lines.

  Subpanel Tumor Cell Lines                                                   
  --------------------------- ----- ----- ----- ----- ----- ----- ----- ----- -----
  **6a**                      1.4   1.1   1.1   1.3   1.4   0.8   1.0   0.5   1.5
  **7**                       1.1   0.9   1.2   0.9   1.2   0.8   1.3   0.8   1.1
  **9**                       1.2   1.1   1.1   1.0   1.1   0.8   1.0   0.8   1.0
